{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:59:50Z","timestamp":1792241990921,"version":"4.4.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014717","name":"National Natural Science Foundation of China National Outstanding Youth Science Fund Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.autrev.2024.103530","type":"journal-article","created":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T01:13:59Z","timestamp":1710638039000},"page":"103530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence"],"prefix":"10.1016","volume":"23","author":[{"given":"Xiaoying","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoce","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.autrev.2024.103530_bb0005","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"Jama."},{"issue":"1","key":"10.1016\/j.autrev.2024.103530_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010179","article-title":"Scanning the immunopathogenesis of psoriasis","volume":"19","author":"Chiricozzi","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2024.103530_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/2468422807666180320125713","article-title":"Biomarkers insights in psoriasis - regulatory cytokines","volume":"7","author":"Surcel","year":"2018","journal-title":"Curr Biomarkers."},{"key":"10.1016\/j.autrev.2024.103530_bb0020","first-page":"1","article-title":"Targeting IL-23 in psoriasis: current perspectives","volume":"8","author":"Fotiadou","year":"2018","journal-title":"Psoriasis (Auckland, NZ)"},{"issue":"2","key":"10.1016\/j.autrev.2024.103530_bb0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cei.13449","article-title":"IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa","volume":"201","author":"Fletcher","year":"2020","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103530_bb0030","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/S0149-2918(02)80075-3","article-title":"Immunogenicity of therapeutic proteins: clinical implications and future prospects","volume":"24","author":"Schellekens","year":"2002","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.autrev.2024.103530_bb0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40257-015-0131-y","article-title":"Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate","volume":"16","author":"Farhangian","year":"2015","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103530_bb0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/jid.2014.295","article-title":"Immunogenicity of biotherapy used in psoriasis: the science behind the scenes","volume":"135","author":"Jullien","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103530_bb0045","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.143.6.719","article-title":"Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis","volume":"143","author":"Tyring","year":"2007","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103530_bb0050","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103530_bb0055","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1346-8138.2012.01679.x","article-title":"Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis","volume":"40","author":"Takahashi","year":"2012","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103530_bb0060","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/j.1365-2133.2011.10555.x","article-title":"Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction","volume":"165","author":"Hoffmann","year":"2011","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103530_bb0065","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.autrev.2024.103530_bb0070","series-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","author":"Page","year":"2020"},{"key":"10.1016\/j.autrev.2024.103530_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Clin Res ed)"},{"issue":"9","key":"10.1016\/j.autrev.2024.103530_bb0080","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.autrev.2024.103530_bb0085","series-title":"Joanna Briggs institute Reviewers\u2019 Manual","author":"Tjb Institute","year":"2016"},{"issue":"11","key":"10.1016\/j.autrev.2024.103530_bb0090","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.autrev.2024.103530_bb0095","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.autrev.2024.103530_bb0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Dersimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"4","key":"10.1016\/j.autrev.2024.103530_bb0105","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2307\/2529268","article-title":"The estimation and interpretation of attributable risk in health research","volume":"32","author":"Walter","year":"1976","journal-title":"Biometrics."},{"key":"10.1016\/j.autrev.2024.103530_bb0110","article-title":"Predictors of drug survival of biologic therapies in psoriasis patients","volume":"1-6","author":"Zorlu","year":"2020","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.autrev.2024.103530_bb0115","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/jdv.14605","article-title":"Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study","volume":"32","author":"Gerdes","year":"2018","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"7","key":"10.1016\/j.autrev.2024.103530_bb0120","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/09546634.2017.1296927","article-title":"Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study","volume":"28","author":"Ara-Mart\u00edn","year":"2017","journal-title":"J Dermatol Treatment"},{"issue":"9","key":"10.1016\/j.autrev.2024.103530_bb0125","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/1346-8138.13301","article-title":"Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-\u03b1 level and the efficacy of TNF-inhibitor therapy in psoriasis","volume":"43","author":"Kui","year":"2016","journal-title":"J Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2024.103530_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167757","article-title":"Anti-TNF-alpha drugs differently affect the TNF alpha-sTNFR system and monocyte subsets in patients with psoriasis","volume":"11","author":"Gibellini","year":"2016","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.autrev.2024.103530_bb0135","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s11096-016-0343-0","article-title":"Positive correlation between etanercept concentration and the decrease in psoriasis area and severity index scale value","volume":"38","author":"Elberdin","year":"2016","journal-title":"Int J Clin Pharmacy"},{"issue":"2","key":"10.1016\/j.autrev.2024.103530_bb0140","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjd.12341","article-title":"Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study","volume":"169","author":"Mahil","year":"2013","journal-title":"Br J Dermatol"},{"issue":"9504","key":"10.1016\/j.autrev.2024.103530_bb0145","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet (London, England)."},{"issue":"4","key":"10.1016\/j.autrev.2024.103530_bb0150","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/bjd.12791","article-title":"Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis","volume":"170","author":"Bito","year":"2014","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103530_bb0155","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/bjd.12404","article-title":"Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)","volume":"168","author":"Reich","year":"2013","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.autrev.2024.103530_bb0160","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1346-8138.2010.00882.x","article-title":"Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: a pilot study","volume":"37","author":"Adi\u015fen","year":"2010","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103530_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"9494","key":"10.1016\/j.autrev.2024.103530_bb0170","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2024.103530_bb0175","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103530_bb0180","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/14712598.2021.1851362","article-title":"Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized phase III VOLTAIRE-PSO study","volume":"21","author":"Menter","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.autrev.2024.103530_bb0185","first-page":"735","article-title":"Efficacy, safety and immunogenicity of AVT02 versus originator adalimumab in subjects with moderate to severe chronic plaque psoriasis: a multicentre, double-blind, randomised, parallel group, active control, phase III study","volume":"35","author":"Feldman","year":"2021","journal-title":"BioDrugs Clin Immunotherap Biopharm Gene Ther"},{"issue":"8","key":"10.1016\/j.autrev.2024.103530_bb0190","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jid.2019.02.018","article-title":"Immunogenicity of guselkumab is not clinically relevant in patients with moderate-to-severe plaque psoriasis","volume":"139","author":"Zhu","year":"2019","journal-title":"J Investig Dermatol."},{"issue":"2","key":"10.1016\/j.autrev.2024.103530_bb0195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15570\/actaapa.2017.10","article-title":"Importance of immunogenicity testing for cost-effective management of psoriasis patients treated with adalimumab","volume":"26","author":"Mota","year":"2017","journal-title":"Acta Dermatovenerol Alpina, Pannonica, et Adriatica"},{"issue":"12","key":"10.1016\/j.autrev.2024.103530_bb0200","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011941","article-title":"Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence","volume":"6","author":"Lombardi","year":"2016","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.autrev.2024.103530_bb0205","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1001\/jamadermatol.2014.5479","article-title":"Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis: a step toward personalized treatment","volume":"151","author":"Menting","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103530_bb0210","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2340\/00015555-2069","article-title":"Risk factor analysis for the immunogenicity of adalimumab associated with decreased clinical response in Chinese patients with psoriasis","volume":"95","author":"Chiu","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103530_bb0215","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jamadermatol.2013.8347","article-title":"Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up","volume":"150","author":"Menting","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103530_bb0220","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2133.2010.10139.x","article-title":"Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy","volume":"164","author":"Papp","year":"2011","journal-title":"Brit J Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103530_bb0225","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/archdermatol.2009.347","article-title":"Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis","volume":"146","author":"Lecluse","year":"2010","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103530_bb0230","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103530_bb0235","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/cts.12725","article-title":"Using real-world data to guide ustekinumab dosing strategies for psoriasis: a prospective pharmacokinetic-pharmacodynamic study","volume":"13","author":"Pan","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"11","key":"10.1016\/j.autrev.2024.103530_bb0240","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jid.2020.03.957","article-title":"Clinical impact of antibodies against ustekinumab in psoriasis: an observational, cross-sectional, multicenter study","volume":"140","author":"Loeff","year":"2020","journal-title":"J Investig Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103530_bb0245","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jaad.2019.05.094","article-title":"Immunogenicity and skin clearance recapture in clinical studies of brodalumab","volume":"82","author":"Bagel","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103530_bb0250","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/jamadermatol.2019.1783","article-title":"Association of serum ustekinumab levels with clinical response in psoriasis","volume":"155","author":"Tsakok","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103530_bb0255","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/bjd.13834","article-title":"The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting","volume":"173","author":"Menting","year":"2015","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.autrev.2024.103530_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142930","article-title":"The association between clinical response to ustekinumab and immunogenicity to ustekinumab and prior adalimumab","volume":"10","author":"Chiu","year":"2015","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.autrev.2024.103530_bb0265","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","article-title":"Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)","volume":"63","author":"Tsai","year":"2011","journal-title":"J Dermatol Sci"},{"issue":"9625","key":"10.1016\/j.autrev.2024.103530_bb0270","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"The Lancet."},{"issue":"9625","key":"10.1016\/j.autrev.2024.103530_bb0275","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.autrev.2024.103530_bb0280","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaad.2019.11.040","article-title":"Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials","volume":"82","author":"Reich","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103530_bb0285","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09546634.2019.1587145","article-title":"Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study","volume":"31","author":"Ferris","year":"2020","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"10.1016\/j.autrev.2024.103530_bb0290","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/bjd.17454","article-title":"Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies","volume":"180","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2024.103530_bb0295","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","article-title":"Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study","volume":"139","author":"Gordon","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103530_bb0300","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/1346-8138.14504","article-title":"Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study","volume":"45","author":"Ohtsuki","year":"2018","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103530_bb0305","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103530_bb0310","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103530_bb0315","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103530_bb0320","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103530_bb0325","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/bjd.17918","article-title":"Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab","volume":"182","author":"Kimball","year":"2020","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103530_bb0330","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjd.13932","article-title":"Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"issue":"7551","key":"10.1016\/j.autrev.2024.103530_bb0335","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature14175","article-title":"Clinical improvement in psoriasis with specific targeting of interleukin-23","volume":"521","author":"Kopp","year":"2015","journal-title":"Nature."},{"issue":"10","key":"10.1016\/j.autrev.2024.103530_bb0340","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40262-019-00759-z","article-title":"Population pharmacokinetics of risankizumab in healthy volunteers and subjects with moderate to severe plaque psoriasis: integrated analyses of phase I-III clinical trials","volume":"58","author":"Suleiman","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10.1016\/j.autrev.2024.103530_bb0345","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/1346-8138.14941","article-title":"Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2\/3 trial","volume":"46","author":"Ohtsuki","year":"2019","journal-title":"J Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2024.103530_bb0350","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/jcph.1473","article-title":"Pharmacokinetics of risankizumab in Asian healthy subjects and patients with moderate to severe plaque psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis","volume":"59","author":"Khatri","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"16","key":"10.1016\/j.autrev.2024.103530_bb0355","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2024.103530_bb0360","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/bjd.18331","article-title":"Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2\u00b75-year results from GESTURE, a randomized, double-blind, placebo-controlled trial","volume":"182","author":"Gottlieb","year":"2020","journal-title":"Br J Dermatol"},{"issue":"22","key":"10.1016\/j.autrev.2024.103530_bb0365","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1097\/CM9.0000000000001163","article-title":"Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis","volume":"133","author":"Cai","year":"2020","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"10.1016\/j.autrev.2024.103530_bb0370","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1111\/jdv.15637","article-title":"Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years","volume":"33","author":"Reich","year":"2019","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"10","key":"10.1016\/j.autrev.2024.103530_bb0375","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/1346-8138.13900","article-title":"Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: subanalysis from ERASURE phase III study","volume":"44","author":"Wu","year":"2017","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103530_bb0380","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/bjd.14965","article-title":"Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis","volume":"176","author":"Reich","year":"2017","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103530_bb0385","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/jdv.14073","article-title":"Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial","volume":"31","author":"Lacour","year":"2017","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"3","key":"10.1016\/j.autrev.2024.103530_bb0390","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bjd.15656","article-title":"Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis","volume":"177","author":"Blauvelt","year":"2017","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103530_bb0395","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/bjd.15706","article-title":"Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study","volume":"177","author":"Bissonnette","year":"2017","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103530_bb0400","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/bjd.13814","article-title":"Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)","volume":"173","author":"Tha\u00e7i","year":"2015","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103530_bb0405","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE)","volume":"29","author":"Paul","year":"2015","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"1","key":"10.1016\/j.autrev.2024.103530_bb0410","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","article-title":"Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE)","volume":"73","author":"Mrowietz","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103530_bb0415","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2024.103530_bb0420","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/1346-8138.12668","article-title":"Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study","volume":"41","author":"Ohtsuki","year":"2014","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103530_bb0425","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2024.103530_bb0430","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.12070","article-title":"Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study","volume":"168","author":"Rich","year":"2013","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103530_bb0435","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103530_bb0440","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/1346-8138.15733","article-title":"Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: a randomized, phase III, double-blind, placebo-controlled study","volume":"48","author":"Seo","year":"2021","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103530_bb0445","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/1346-8138.15343","article-title":"Long-term safety of brodalumab in Japanese patients with plaque psoriasis: an open-label extension study","volume":"47","author":"Yamaguchi","year":"2020","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103530_bb0450","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/bjd.19132","article-title":"Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1)","volume":"183","author":"Papp","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103530_bb0455","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bjd.14702","article-title":"Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study","volume":"176","author":"Yamasaki","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103530_bb0460","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","article-title":"Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study","volume":"81","author":"Nakagawa","year":"2016","journal-title":"J Dermatol Sci"},{"issue":"14","key":"10.1016\/j.autrev.2024.103530_bb0465","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2024.103530_bb0470","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.jaad.2014.08.039","article-title":"Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment","volume":"71","author":"Papp","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103530_bb0475","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jdermsci.2014.05.007","article-title":"Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study","volume":"75","author":"Osamu","year":"2014","journal-title":"J Dermatol Sci"},{"issue":"13","key":"10.1016\/j.autrev.2024.103530_bb0480","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2024.103530_bb0485","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jdv.15292","article-title":"Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab","volume":"33","author":"Umezawa","year":"2019","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"10","key":"10.1016\/j.autrev.2024.103530_bb0490","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.jid.2018.04.019","article-title":"Ixekizumab pharmacokinetics, anti-drug antibodies, and efficacy through 60 weeks of treatment of moderate to severe plaque psoriasis","volume":"138","author":"Reich","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103530_bb0495","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/1346-8138.13622","article-title":"Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J)","volume":"44","author":"Saeki","year":"2017","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103530_bb0500","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdv.14163","article-title":"Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis","volume":"31","author":"Blauvelt","year":"2017","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"4","key":"10.1016\/j.autrev.2024.103530_bb0505","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2024.103530_bb0510","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/bjd.20827","article-title":"Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study","volume":"186","author":"Oliver","year":"2022","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103530_bb0515","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/bcp.13185","article-title":"First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis","volume":"83","author":"Glatt","year":"2017","journal-title":"Br J Clin Pharmacol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224000211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224000211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T17:24:26Z","timestamp":1715361866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224000211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1568997224000211"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103530","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103530","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103530"}}